Get the Stockscreener App
1.845
2.13%
-0.035
Medicinova Inc stock is traded at $1.845, with a volume of 57,501.
It is down -2.13% in the last 24 hours and up +44.88% over the past month.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
See More
Previous Close:
$1.88
Open:
$1.86
24h Volume:
57,501
Relative Volume:
0.07
Market Cap:
$90.18M
Revenue:
$134.60K
Net Income/Loss:
$-11.81M
P/E Ratio:
-7.6588
EPS:
-0.2409
Net Cash Flow:
$-10.05M
1W Performance:
+9.52%
1M Performance:
+44.88%
6M Performance:
+26.03%
1Y Performance:
-4.66%
1-Day Range:
$1.835
$1.88
1-Week Range:
$1.55
$1.915
52-Week Range:
$1.13
$2.06
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.835 | 92.39M | 134.60K | -11.81M | -10.05M | -0.2409 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.51 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.61 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.92 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving AverageWhat's Next? - MarketBeat
Institution Moves: What are the risks of holding Real Messenger CorporationTrade Ideas & Consistent Return Investment Signals - baoquankhu1.vn
MNOVMediciNova Reports Third Quarter 2011 Results - ADVFN
Dip Buying: Can MediciNova Inc continue delivering strong returnsTrade Signal Summary & Short-Term High Return Ideas - baoquankhu1.vn
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th Int... - ADVFN
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average – Should You Sell? - Defense World
Price Action: How sensitive is MediciNova Inc to inflationMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Aug Patterns: Why MediciNova Inc. stock could benefit from AI revolutionMarket Growth Summary & Long-Term Capital Growth Strategies - Bộ Nội Vụ
Rate Hike: Why MediciNova Inc. stock could benefit from AI revolution2025 Trading Recap & Accurate Buy Signal Alerts - Bộ Nội Vụ
Columbia University/New York State Psychiatric Institute and MediciNova Report Preliminary Safety and Efficacy of Ibudilast in H - ADVFN
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - ADVFN
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Methamphetamine Dependence - ADVFN
Insider Buy: Will MediciNova Inc stock outperform value stocksJuly 2025 Action & Low Volatility Stock Recommendations - moha.gov.vn
Why MediciNova Inc. stock could benefit from AI revolutionMarket Trend Report & Expert Approved Momentum Trade Ideas - Улправда
Will MediciNova Inc. stock beat EPS estimatesPortfolio Gains Summary & Weekly High Conviction Trade Ideas - Улправда
MediciNova Receives a Notice of Allowance for a Method of Treating Drug Addiction or Dependence - ADVFN
Whale Trades: Why MediciNova Inc. stock could benefit from AI revolutionBear Alert & AI Driven Price Forecasts - Улправда
Is MediciNova Inc. stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
Is MediciNova Inc. stock a dividend growth opportunityJuly 2025 Retail & AI Enhanced Execution Alerts - Улправда
Short Covering: Will MediciNova Inc. stock outperform value stocksTrade Ideas & Free Expert Verified Stock Movement Alerts - ulpravda.ru
MediciNova (NASDAQ:MNOV) Rating Increased to Strong-Buy at Lucid Cap Mkts - MarketBeat
MediciNova, Inc. Provides Shareholder Update on Clinical Trials and Strategic Developments for 2026 - Quiver Quantitative
2026 New Year’s Greetings from the CEO - The Manila Times
MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average – What’s Next? - Defense World
MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’... - ADVFN
Retail Trends: Is MediciNova Inc stock a top pick in earnings seasonWeekly Profit Recap & High Conviction Buy Zone Picks - moha.gov.vn
4875.T Jumps 8.7% Today: Positive Momentum in Biotech - Meyka
MediciNova enters $50 million equity distribution agreement with Lucid Capital - Investing.com Nigeria
MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets - MarketScreener
Medicinova IncOn Dec 29, Entered $50 Million Equity Distribution Agreement With Lucid Capital Markets- SEC Filing - TradingView — Track All Markets
MediciNova Establishes Flexible At-The-Market Equity Program - TipRanks
MediciNova enters $50 million equity distribution agreement with Lucid Capital By Investing.com - Investing.com South Africa
MediciNova Signs Equity Distribution Agreement With Lucid Capital Markets - TradingView — Track All Markets
Form 424B5 MEDICINOVA INC - StreetInsider
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decline in Short Interest - MarketBeat
Is MediciNova Inc. stock a top pick in earnings seasonWeekly Investment Summary & Growth Focused Entry Point Reports - Bölüm Sonu Canavarı
Will MediciNova Inc. stock outperform value stocksDollar Strength & Real-Time Stock Movement Alerts - DonanımHaber
MediciNova (NASDAQ:MNOV) Receives Buy Rating from D. Boral Capital - Defense World
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
How MediciNova Inc. stock performs in rising dollar environmentEarnings Performance Report & Community Shared Stock Ideas - Улправда
MediciNova completes enrollment in chemotherapy neuropathy trial By Investing.com - Investing.com Nigeria
MNOV: Analyst Jason Kolbert Maintains 'Buy' Rating with $9 Price - GuruFocus
D. Boral Capital Reaffirms Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug - marketscreener.com
MediciNova completes enrollment in chemotherapy neuropathy trial - Investing.com India
MediciNova, Inc. Completes Patient Enrollment in Phase 2 OXTOX Study for MN-166 in Metastatic Colorectal Cancer Patients - Quiver Quantitative
MediciNova Announces Completion of Patient Enrollment - GlobeNewswire
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):